Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...
Find MoreThe industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.